Tanvi Joshi1, Ishani Patel1, Avinash Kumar1, Virginia Donovan2, Anait S Levenson3. 1. Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, 11201, USA. 2. NYU Winthrop Hospital, Mineola, NY, 11501, USA. 3. School of Veterinary Medicine, Long Island University, Brookville, NY, 11548, USA.
Abstract
SCOPE: Previous studies have identified potent anticancer activities of polyphenols in preventing prostate cancer. The aim of the current study is to evaluate the chemopreventive potential of grape powder (GP) supplemented diets in genetically predisposed and obesity-provoked prostate cancer. METHODS AND RESULTS: Prostate-specific Pten heterozygous (Pten+/f ) transgenic mice are fed low- and high-fat diet (LFD and HFD, respectively) supplemented with 10% GP for 33 weeks, ad libitum. Prostate tissues are characterized using immunohistochemistry and western blots, and sera are analyzed by ELISA and qRT-PCR. Pten+/f mice fed LFD and HFD supplemented with 10% GP show favorable histopathology, significant reduction of the proliferative rate of prostate epithelial cells (Ki67), and rescue of PTEN expression. The most potent protective effect of GP supplementation is detected against HFD-induced increase in inflammation (IL-1β; TGF-β1), activation of cell survival pathways (Akt, AR), and angiogenesis (CD31) in Pten+/f mice. Moreover, GP supplementation reduces circulating levels of oncogenic microRNAs (miR-34a; miR-22) in Pten+/f mice. There are no significant changes in body weight and food intake in GP supplemented diet groups. CONCLUSIONS: GP diet supplementation can be a beneficial chemopreventive strategy for obesity-related inflammation and prostate cancer progression. Monitoring serum miRNAs can facilitate the non-invasive evaluation of chemoprevention efficacy.
SCOPE: Previous studies have identified potent anticancer activities of polyphenols in preventing prostate cancer. The aim of the current study is to evaluate the chemopreventive potential of grape powder (GP) supplemented diets in genetically predisposed and obesity-provoked prostate cancer. METHODS AND RESULTS: Prostate-specific Pten heterozygous (Pten+/f ) transgenic mice are fed low- and high-fat diet (LFD and HFD, respectively) supplemented with 10% GP for 33 weeks, ad libitum. Prostate tissues are characterized using immunohistochemistry and western blots, and sera are analyzed by ELISA and qRT-PCR. Pten+/f mice fed LFD and HFD supplemented with 10% GP show favorable histopathology, significant reduction of the proliferative rate of prostate epithelial cells (Ki67), and rescue of PTEN expression. The most potent protective effect of GP supplementation is detected against HFD-induced increase in inflammation (IL-1β; TGF-β1), activation of cell survival pathways (Akt, AR), and angiogenesis (CD31) in Pten+/f mice. Moreover, GP supplementation reduces circulating levels of oncogenic microRNAs (miR-34a; miR-22) in Pten+/f mice. There are no significant changes in body weight and food intake in GP supplemented diet groups. CONCLUSIONS:GP diet supplementation can be a beneficial chemopreventive strategy for obesity-related inflammation and prostate cancer progression. Monitoring serum miRNAs can facilitate the non-invasive evaluation of chemoprevention efficacy.
Authors: Swati Dhar; Avinash Kumar; Christian R Gomez; Israh Akhtar; John C Hancock; Janice M Lage; Charles R Pound; Anait S Levenson Journal: FEBS Lett Date: 2017-03-12 Impact factor: 4.124
Authors: Stefan Ambs; Robyn L Prueitt; Ming Yi; Robert S Hudson; Tiffany M Howe; Fabio Petrocca; Tiffany A Wallace; Chang-Gong Liu; Stefano Volinia; George A Calin; Harris G Yfantis; Robert M Stephens; Carlo M Croce Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: Channing J Paller; Xian C Zhou; Elisabeth I Heath; Mary-Ellen Taplin; Tina Mayer; Mark N Stein; Glenn J Bubley; Roberto Pili; Tamaro Hudson; Radhika Kakarla; Muneer M Abbas; Nicole M Anders; Donna Dowling; Serina King; Ashley B Bruns; William D Wagner; Charles G Drake; Emmanuel S Antonarakis; Mario A Eisenberger; Samuel R Denmeade; Michelle A Rudek; Gary L Rosner; Michael A Carducci Journal: Clin Cancer Res Date: 2017-11-07 Impact factor: 12.531
Authors: Vijayalakshmi Ananthanarayanan; Ryan J Deaton; Ximing J Yang; Michael R Pins; Peter H Gann Journal: BMC Cancer Date: 2006-03-17 Impact factor: 4.430